British American Tobacco p.l.c. · LSE:BATS

British American Tobacco p.l.c — Investor Day (November 2016)

54 slides from British American Tobacco p.l.c's investor day presentation, Nov 17, 2016

  1. Slide 1: "The material in this presentation is provided for the purpose of giving information about

    "The material in this presentation is provided for the purpose of giving information about us to investors and is not provided for tobacco product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a soli

  2. Slide 2: Inspiring Products. Driving Change.

    INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S

  3. Slide 3: Inspiring Products. Driving Change. Nicandro Durante

    INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Nicandro Durante Chief Executive Officer

  4. Slide 4: Our Next Generation Products Journey

    OUR NEXT GENERATION PRODUCTS JOURNEY INSPIRING Substantial Share Of P RO D U C T S . £15BN DRIVING NGP Category CHANGE. by 2020

  5. Slide 5: Inspiring Products. Driving Change. Kingsley Wheaton

    INSPIRING PRODUCTS. DRIVING CHANGE . L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Kingsley Wheaton Managing Director – Next Generation Products

  6. Slide 6: Agenda

    AGENDA 01 AMBITION 02 INSPIRING PRODUCTS. DRIVING CHANGE. 03 R&D & SCIENCE 04 LEADING IN VAPOUR 05 THE NEW TASTE SENSATION 06 CONCLUSIONS

  7. Slide 7: Inspiring Products. Driving Change.

    INSPIRING PRODUCTS. DRIVING CHANGE. ____ Substantial share of £15BN NGP Category by 2020

  8. Slide 8: Portfolio

    INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns

  9. Slide 9: More Choice, More Innovation, Potentially Less Harm

    MORE CHOICE, MORE INNOVATION, POTENTIALLY LESS HARM TOBACCO HEATING PLATFORM HYBRID CLOSED VAPOUR SYSTEMS OPEN VAPOUR SYSTEMS PRODUCTS CONTAINING Tobacco Tobacco & eLiquid eLiquid eLiquid Tobacco sensorials Simplicity Performance Tobacco affinity Simplicity CONSUMER NEEDS Flavour exploration Customi

  10. Slide 10: Creating Inspiring Products. Driving Change.

    CREATING INSPIRING PRODUCTS. DRIVING CHANGE. INSPIRING PRODUCTS. DRIVING CHANGE. CLEAR, CONFRONTING OUTSTANDING SIMPLE INSPIRING TOXICANT UNAMBIGUOUS MISINFORMATION SENSORIAL & INTUITIVE PRODUCT REDUCTION CONSUMER & MYTHS EXPERIENCES SYSTEMS DESIGN & USER & CLAIMS INFORMATION HEAD-ON EXPERIENCE INDU

  11. Slide 11: Differentiated Branding: Because Consumers Are Not Homogenous

    DIFFERENTIATED BRANDING: BECAUSE CONSUMERS ARE NOT HOMOGENOUS TOBACCO HEATED PLATFORM HYBRID VAPOUR SYSTEMS PRODUCTS HIGHER LOWER TOBACCO TOBACCO AFFINITY AFFINITY DEVICE BRANDING DEVICE BRANDING LUCKY STRIKE ROTHMANS LUCKY STRIKE PALL MALL GLOBAL ROTHMANS PALL MALL DUNHILL DUNHILL DRIVE CONSUMABLE

  12. Slide 12: Branding

    INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns

  13. Slide 13: Dr. David O'Reilly, Group Scientific and R&D Director

    INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Dr. David O’Reilly Group Scientific and R&D Director

  14. Slide 14: Harm Reduction and the Model Risk Continuum

    HARM REDUCTION AND THE MODEL RISK CONTINUUM TOBACCO LOW TOXICANT LICENSED CONVENTIONAL ELECTRONIC HEATING SMOKELESS MEDICIAL CIGARETTES CIGARETTES PRODUCTS TOBACCO PRODUCTS HIGH EXPOSURE TO TOXICANTS LOW LOW TOXICANT SMOKELESS TOBACCO LICENSED MEDICINAL PRODUCTS TOBACCO HEATING PRODUCTS? CONVENTIONA

  15. Slide 15: Industry-Leading Tools to Substantiate Reduced Risk

    WE ARE USING INDUSTRY-LEADING TOOLS TO SEEK TO SUBSTANTIATE REDUCED RISK ACROSS OUR NEXT GENERATION PRODUCTS Potential Potential

  16. Slide 16: A Three-Step Scientific Journey to Substantiate Reduced Risk

    A THREE-STEP SCIENTIFIC JOURNEY TO SEEK TO SUBSTANTIATE REDUCED RISK 01 02 03 EMISSIONS EXPOSURE RISK Chemical studies in laboratories using One week human studies demonstrating 6–12 month human studies demonstrating smoking/vaping machines comparing switching to NGPs results in lower changes on swi

  17. Slide 17: Our NGPs Deliver a Different Aerosol to Cigarette Smoke

    OUR NGPs DELIVER A DIFFERENT AEROSOL TO CIGARETTE SMOKEa › Cigarettes burn tobacco at around 900˚Cb › glo™ heats tobacco up to a maximum of 240˚Cc › Vype™ heats liquids at around 250˚C aThese qualities do not necessarily mean this product produces less adverse health effects than other tobacco produ

  18. Slide 18: glo and Vype Produce a Different Aerosol Versus a Cigarette

    glo™ & Vype™ PRODUCE A DIFFERENT AEROSOL VERSUS A CIGARETTEa,b MACHINE GENERATED AEROSOL CONDENSATE COLLECTED ON FILTER PADS cigarette glo™ Vype™ The glo™ and Vype™ aerosol collected on a glass fibre pad does not contain all the tar related substances of cigarette smoke aMachine puffing conducted un

  19. Slide 19: Next Generation Product Emissions

    NEXT GENERATION PRODUCT EMISSIONS COMPARISON OF NGP EMISSIONS AGAINST A SCIENTIFIC REFERENCE CIGARETTEa Cigarette smoke glo™ emissions Vype™ emissions Simpler aerosol composed of fewer constituents aChemical screening of emissions from a scientific reference cigarette (3R4F), glo and vype using a co

  20. Slide 20: Our NGPs Deliver Around 90% Less Toxicants Versus Cigarette Smoke

    OUR NGPs DELIVER AROUND 90% LESS TOXICANTS VERSUS CIGARETTE SMOKEa 100% Reference reference 9mg cigarette (3R4F) cigarette Acetaldehyde Acrolein Formaldehyde Carbon monoxide (CO) TOXICANT LEVELS Benzo[a]pyrene 1,3-Butadiene glo vype Benzene N-Nitrosnornicotine (NNN) 4-(Methylnitrosamino)-1- ≥ 90% (3

  21. Slide 21: Emissions Continuum

    EMISSIONS CONTINUUMa,b % TOXICANTS REDUCTIONS VS 3R4F on WHO 9 TOXICANT LIST O 100 3R4F Best 1mg/cig ‘Tar’ reference 45% ≥ 90% ≥95% % TOXICANTS REDUCTIONS VS BEST 1MG/CIG ‘TAR’ CIGARETTE on WHO 9 TOXICANT LIST O 100 Best 1 mg/cig ‘Tar’ ≈75% ≥95% aThis graph represents an emissions continuum, further

  22. Slide 22: Relative In Vitro Toxicity

    RELATIVE IN VITRO TOXICITYA SUBSTANTIALLY LOWER TOXICITY FOR glo™ (DEVELOPMENT PROTOTYPE) AND Vype™ aComparison of glo (development prototype) and Vype versus a scientific reference cigarette (3R4F). These qualities do not necessarily mean that Glo and Vype products produce less adverse health effec

  23. Slide 23: Risk Assessment Needs Clinical Studies as Dose Response Is Key

    RISK ASSESSMENT NEEDS CLINICAL STUDIES AS DOSE RESPONSE IS KEY Model Model v v Dose response model A shows that low emissions/exposure relates to low risk, whereas dose response model B shows that even at low emissions/exposure the risk is high

  24. Slide 24: Systems Science, Clinical Studies and Adverse Outcome Pathways

    WE ARE USING SYSTEMS SCIENCE, CLINICAL STUDIES AND ADVERSE OUTCOME PATHWAYS FOR RISK ASSESSMENT e-cig 3R4F Systems Sciencea Adverse Outcome Pathwaysb SHORT AND LONG-TERM CLINICAL STUDIES aExemplar of comparative assessment of Vype and 3R4F using next generation sequencing; bExemplar of one of our AO

  25. Slide 25: Our Plan to Assess Risk Reduction Potential of glo and Vype

    OUR PLAN TO ASSESS THE RISK REDUCTION POTENTIAL OF glo™ AND VYPE Q3 Q4 H1 H2 H1 H2 H1 2016 2016 2017 2017 2018 2018 2019 Reduced emissions and performance claims Reduced toxicity in lab models Reduced exposure Reduced risk Wave 2: Systems Science Wave 3: Systems Science Wave 1: Systems Science & AOP

  26. Slide 26: Other benefits of NGPs

    » Other a benefits of NGPs

  27. Slide 27: Less Odour and Reduced Impact on Indoor Air Quality

    OUR NGPs PRODUCE LESS ODOUR AND REDUCE THE IMPACT ON INDOOR AIR QUALITYa INDOOR AIR QUALITY TESTS a ODOUR ASSESSMENT TEST b 4.0E+05 3.5E+05 3.0E+05 2.5E+05 N/cc 2.0E+05 ________ Cigarette 1.5E+05 ________ Glo 1.0E+05 5.0E+04 0.0E+00 0 0.5 1 1.5 2 2.5 3 3.5 4 Time, h Comparative assessment of the imp

  28. Slide 28: Conclusions

    CONCLUSIONS • Our NGPs operate in a different manner to cigarettes producing simpler and cleaner aerosols than smoke • Our NGPs have reduced levels of toxicants compared to cigarettes • Vype™ shows greater reduction of toxicant emissions than THPs • Vype™ and glo™ have the potential to be reduced ri

  29. Slide 29: Vapour

    VAPOUR

  30. Slide 30: The Largest Vapour Business in the World Outside the USA

    THE LARGEST VAPOUR BUSINESS IN THE WORLD OUTSIDE THE USA 55-60% 34.6% 8.6% 4.8% 2.1% All Market Nielsen Retail Audit*, 6MMA Share Internal estimates, retail channel* Internal estimates, retail channel* Internal estimates, retail channel* share, 6MMA share, 6MMA *Retail excludes specialist vape store

  31. Slide 31: Indexed Volume Performance

    INDEXED VOLUME PERFORMANCE 900 800 711* UK 700 695 Germany 600 630 Poland 500 400 300 309 Italy 200 226 Romania** 186 France 100 0 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 *UK Index based on Jan ‘15 sales **iFuse

  32. Slide 32: Vapour – The Largest NGP Category by Value

    VAPOUR – THE LARGEST NGP CATEGORY BY VALUE GLOBAL SALES OF VAPOUR (£BN) 8 6 4 2 0 2010 2011 2012 2013 2014 2015 2016 Source: Euromonitor

  33. Slide 33: 56% Are Returners, Quitters or New Users

    56% ARE RETURNERS, QUITTERS OR NEW USERS CONSUMERS BY SMOKING CHARACTERISTICS (% OF USERS) Source: Source: Kantar, Kantar, EY EY analysis Seven markets, UK,analysis Germany, Poland, France, Italy, Russia & South Korea

  34. Slide 34: Usage Rates Continue to Grow Consistently

    USAGE RATES CONTINUE TO GROW CONSISTENTLY CONSUMERS (BOTH REGULAR AND OCCASIONAL) AS A PERCENTAGE OF ADULTS, 2013-2016 Source: Kantar, EY analysis Seven markets, UK, Germany, Poland, France, Italy, Russia & South Korea

  35. Slide 35: Only 25% of Vapours Use a Tobacco Flavour

    ONLY 25% OF VAPOURS USE A TOBACCO FLAVOUR MOST OFTEN USED E-LIQUID FLAVOUR (PERCENTAGE OF USERS) 2015 -2016 Source: Source: Kantar, Kantar, EY EY analysis analysis Seven markets, UK, Germany, Poland, France, Italy, Russia & South Korea

  36. Slide 36: Vapour Converts Substantially More CPTO to Margin

    VAPOUR CONVERTS SUBSTANTIALLY MORE CPTO TO MARGIN € Per unit WAP FMC Vype vPro € Per unit WAP FMC Vype Liquid GM as % of RRP 12.9% 27.4% GM as % of RRP 6.2% 28.0% Absolute €0.58 €1.90 Absolute €0.16 €1.19 % OF CPTO % OF CPTO 100% 100% 90% 90% 80% 80% Tax Tax 70% 70% 60% 60% Trade Trade 50% margin 50

  37. Slide 37: Introducing Vype Pebble

    INTRODUCING VYPE PEBBLE

  38. Slide 38: Small and Mighty

    SMALL AND MIGHTY BLUE’S THE DADDY THE NEXT SMALL THING SMALL DARK & HANDSOME AWESOME AND SOME POCKET ROCKET

  39. Slide 39: Vype Pebble Features & Benefits

    VYPE PEBBLE FEATURES & BENEFITS CARTRIDGE GOLDEN VELVET TINGLING TOBACCO TOBACCO MINT  Palm fit size, ergonomic, poke- DESIGN nomics, easy to use, stylish, range of colours  All day charge, elegant design POWERFUL & INTUITIVE WILD FRESH SMOOTH system BERRIES APPLE VANILLA  Rich satisfying vapour,

  40. Slide 40: Full bleed hero retail image here

    Full bleed hero retail image here

  41. Slide 41: One Touch to Enjoy Next Generation Heating Tobacco glo

    ONE TOUCH TO ENJOY NEXT GENERATION HEATING TOBACCO “gloTM”

  42. Slide 42: Multiple Benefits to the glo System Proposition

    MULTIPLE BENEFITS TO THE GLO SYSTEM PROPOSITION

  43. Slide 43: Multiple Benefits to the glo System Proposition

    MULTIPLE BENEFITS TO THE GLO SYSTEM PROPOSITION

  44. Slide 44: Three Exceptional Flavours, Researched Extensively

    THREE EXCEPTIONAL FLAVOURS, RESEARCHED EXTENSIVELY BRIGHT TOBACCO FRESH MIX INTENSELY FRESH Complex mix Well balanced Exhilarating of mint and & mellow with burst of cooling, velvety notes bright, roasted balanced with balanced with malty notes fresh mint refreshing menthol

  45. Slide 45: World First Coming to Sendai 12.12.16

    “WORLD FIRST COMING TO SENDAI 12.12.16”

  46. Slide 46: Slide 46

  47. Slide 47: We Believe Less Is More

    2°2| NGP gle WE BELIEVE| a LESS IS MORE.

  48. Slide 48: Device Customisation Lends a World of Opportunity

    DEVICE CUSTOMISATION LENDS A WORLD OF OPPORTUNITY DEVICE COLOUR VARIANTS SLEEVES PR INFLUENCERS LIMITED EDITION COLOUR VARIATION

  49. Slide 49: Our First Flagship Store in Sendai

    OUR FIRST FLAGSHIP STORE IN SENDAI

  50. Slide 50: Supply Chain

    INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns

  51. Slide 51: Supply Chain Manufacturing Integration

    SUPPLY CHAIN MANUFACTURING INTEGRATION: CURRENTLY RUSSIA & SOUTH KOREA BUILDING SUBSTANTIAL CAPACITY IN 2017 & 2018 2x 2018 vs 2017

  52. Slide 52: Japan: glo Is More Than 2x Margin vs FMC

    JAPAN: vs FMC CHECK DATA £ Per unit FMC gloTM is more than 2x margin GM as % of RRP 14.1% 36.2% Absolute £0.42 £1.08 generating versus cigarettes % OF CPTO 100% 90% Tax Longer term, COGS profile 80% 70% will reduce as volumes scale Trade 60% margin 50% COGS 40% 30% RRP Fiscal policy based on model 2

  53. Slide 53: Delivering Today. Investing in Tomorrow.

    DELIVERING TODAY. INVESTING IN TOMORROW. Consumer Centric. More innovation, Inspiring Products. more choice, $1bn investment Driving Change less harm so far in NGP Vapour will be the Tobacco Heating Substantial share of largest category will have pockets of strength and £15BN and has can be margin N

  54. Slide 54: Inspiring Products. Driving Change.

    INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S

British American Tobacco — Investor Day (November 2016) on 6ix